8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Mar 2, 2026·SEC
Material company update
Mar 2, 2026·SEC
UroGen Pharma Ltd.(URGN)Earnings, Financials & Key Ratios
URGN•NASDAQ
$37.94
Price updated Jul 2, 2026
AboutUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.Show more
- Revenue$110M+21.4%
- EBITDA-$122M-27.0%
- Net Income-$153M-21.0%
- EPS (Diluted)-3.19-7.8%
- Gross Margin88.66%-1.7%
- EBITDA Margin-111.54%-4.5%
- Operating Margin-113.73%-6.2%
- Net Margin-139.81%+0.4%
URGN Price & Volume
UroGen Pharma Ltd. (URGN) stock price & volume — 10-year historical chart
Loading chart...
Revenue Acceleration Faces Persistent Structural Liquidity Constraints
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Accelerating
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical and liquidity dependence
Key Thesis Takeaways
- UroGen Pharma demonstrates significant top-line momentum with 151.6% year-over-year revenue growth in 2026Q1, yet the company remains challenged by an inability to achieve operating leverage as expenses consistently outpace gross profits.
- While the proprietary RTGel platform maintains robust gross margins exceeding 91%, the firm's reliance on external financing to cover deep negative free cash flow creates a precarious capital structure.
- Investors should monitor the company's ability to transition from high-cost commercialization to sustainable profitability, as the current equity deficit of $124.3 million underscores significant long-term execution risk.
Verdict Logic
while the 151.6% revenue growth rate is impressive, the company's $111.3 million cash balance against a persistent negative operating margin of -39.8% suggests significant dilution risk remains for shareholders.
URGN Growth Metrics
UroGen Pharma Ltd. (URGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years56.22%
3 Years19.49%
TTM52.92%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM3.76%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM13.52%
Return on Capital
10 Years-64.07%
5 Years-66.59%
3 Years-54.7%
Last Year-63.41%
URGN Recent Earnings
UroGen Pharma Ltd. (URGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.47+16.1%
$0.56
Rev
$51M+13.7%
$45M
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$0.54-4.2%
$0.52
Rev
$38M-5.2%
$40M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.69+4.2%
$0.72
Rev
$27M-31.5%
$40M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.05-28.0%
$0.82
Rev
$24M-27.9%
$34M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.47vs $0.56+16.1% | $51Mvs $45M+13.7% |
| Q2 2026 | Mar 2, 2026 | $0.54vs $0.52-4.2% | $38Mvs $40M-5.2% |
| Q4 2025 | Nov 6, 2025 | $0.69vs $0.72+4.2% | $27Mvs $40M-31.5% |
| Q3 2025 | Aug 7, 2025 | $1.05vs $0.82-28.0% | $24Mvs $34M-27.9% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for UroGen Pharma Ltd. (URGN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $37.94 | $1.85B | -11.89 | 21.45% | -139.81% | — | — | |
| $56.08 | $8.1B | -9.96 | — | — | -32.51% | — | |
| $47.41 | $2.73B | -69.72 | 8.63% | -3.74% | -2.73% | — | |
| $10.31 | $1.43B | -1.00 | -2.75% | -43.5% | -50.65% | — | |
| $32.10 | $1.3B | 26.97 | 27.37% | 6.35% | 29.49% | — | |
| $123.60 | $9.09B | -21.13 | — | — | -42.78% | — |
Compare URGN vs Peers
UroGen Pharma Ltd. (URGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
URGN SEC Filings & Documents
UroGen Pharma Ltd. (URGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when URGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
URGN Frequently Asked Questions
UroGen Pharma Ltd. (URGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is UroGen Pharma Ltd.'s revenue?
UroGen Pharma Ltd. (URGN) reported $140.5M in revenue for fiscal year 2025.
How fast is UroGen Pharma Ltd. growing?
UroGen Pharma Ltd. (URGN) grew revenue by 21.4% over the past year. This is strong growth.
Is URGN profitable?
UroGen Pharma Ltd. (URGN) reported a net loss of $133.2M for fiscal year 2025.
Dividend & Returns
What is UroGen Pharma Ltd.'s free cash flow?
UroGen Pharma Ltd. (URGN) had negative free cash flow of $166.0M in fiscal year 2025, likely due to heavy capital investments.